IGFBP7 and acute kidney injury: The FDA approved two biomarkers of renal cell cycle arrest, tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), for assessing the possibility of severe AKI development.